Clinical Trial Update: Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures [Phase 3]

View source ↗

Summary

A Phase 3 study of BAX 855 in severe Hemophilia A patients undergoing surgical procedures has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAX 855

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2018-05-14